Heparins low-molecular

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

fractional heparins; Low molecular weight heparins

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

A further development of classical heparin is fractionated heparin with chain lengths corresponding to a molecular weight of 4000 to 6000 D. This heparin is called low-molecular-weight (LMW) heparin. These are fractions or fragments of heparin from pig intestinal mucosa or bovine lung.
The individual low-molecular-weight heparins differ in their molecular size and activity, so that there is a separate dosage regulation for each low-molecular-weight heparin. NMW heparins are obtained enzymatically from unfractionated heparin with heparinase or by cleavage with isocyanyl nitrite.
In contrast to non-fractionated heparin, the low-molecular-weight heparins bind only to antithrombin III via the pentasaccharide structures and thus act predominantly by inhibiting factor Xa. The molecules of unfractionated heparin contain only 8-14 monosaccharides, so that the effect of low-molecular-weight heparins on antithrombin is significantly lower than that of unfractionated heparins. The ratio of antifactor Xa to antifactor IIa is 2-4:1 for low-molecular-weight heparin and 1:1 for unfractionated heparin.

Spectrum of actionThis section has been translated automatically.

Low molecular weight heparins, similar to unfractionated heparin, stimulate endothelial heparan synthesis and release TFPI from the endothelium. Compared to heparin, the bioavailability is significantly higher, at approx. 90%. Heparins are not placental and can be given in both forms, unfractionated and fractionated, during pregnancy.

Field of application/useThis section has been translated automatically.

In clinical application, especially in postoperative prophylaxis or in the therapy of venous thrombosis, the fractionated and unfractionated heparins are identical in their effect. However, the low-molecular-weight heparins only need to be administered once a day in comparison to the high-molecular-weight ones. The main advantage of low-molecular-weight heparin is that HIT-2 occurs significantly less frequently. Higher doses of heparin are generally required in feverish conditions than at normal body temperature.
Protamine acts as an antidote for heparin therapy. To neutralize 100 units of heparin, 1 mg protamine is needed. Antagonists of heparin are polylysine and platelet factor 4. The risk of bleeding under heparin therapy is 4-6%. Allergies are extremely rare.

Heparin is practically not absorbed in the intestine and is therefore administered subcutaneously. Its bioavailability is 30%.
The monitoring of the therapy with low-molecular-weight heparin is carried out by the anti-F-Xa test or by the Pefakit test (PiCT = prothrombinase-included clotting time). This is a coagulometric test. Another possibility is the use of chromogenic substrates, whereby the substrate is usually associated with p-nitroaniline. The enzymatically released dye is measured photochemically.

PreparationsThis section has been translated automatically.

Low molecular weight heparins (overview)

Designation

Mean molar mass

Manufacturing history

Trade name

Dosage for thrombosis prophylaxis (IE)

Dalteparin sodium

4000-6000

Depolymerization by nitrite cleavage of heparin

Fragmin

1 x 5000

Nadroparin calcium

4500

Fractionation ethanol precipitation

Fraxiparin

1 x 2850

Enoxaparin sodium

4000-5000

Depolymerization of the benzyl ester of heparin

Clexane

1 x 4000

Reviparin sodium

3500-4500

Depolymerization by nitrite cleavage

Clivarin

1 x 1750

Certoparin sodium

5000-7000

Depolymerization by nitrite cleavage

Monoembolex

1 x 3000

Tinzaparin

3000-6000

Heparinase degradation

Innohep Logiparan

1 x 35000

LiteratureThis section has been translated automatically.

  1. Ansell JE (2016) Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options. On J Cardiovasc Drugs 16:163-170.
  2. Feng W et al (2015) Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis. Thromb Res 136:1133-1144.
  3. HA Neumann (2014) The coagulation system. ABW Scientific Publisher GmbH Berlin
  4. Squizzato A et al (2016) Effect of thromboprophylaxis with anticoagulant drugs on the incidence of arterial thrombotic events in medical inpatients: a systematic review. Internal Emerg Med 11:467-476.
  5. Smythe MA et al (2016) Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb thrombolysis 41:165-186.

Authors

Last updated on: 29.10.2020